GILD has a market capitalization of $73,380,487,376 -- more than approximately 97.46% of US stocks.
With a one year PEG ratio of 299.24, Gilead Sciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 88.95% of US stocks.
In terms of volatility of its share price, GILD is more volatile than merely 4.7% of stocks we're observing.
Stocks that are quantitatively similar to GILD, based on their financial statements, market capitalization, and price volatility, are ATVI, ADI, AMAT, BIIB, and RACE.
GILD's SEC filings can be seen here. And to visit Gilead Sciences Inc's official web site, go to www.gilead.com.
Gilead Sciences is a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
GILD Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Gilead Sciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Gilead Sciences Inc ranked in the 30th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Gilead Sciences Inc ended up being:
The company's compound free cash flow growth rate over the past 5.45 years comes in at -0.06%; that's greater than just 17.52% of US stocks we're applying DCF forecasting to.
The company has produced more trailing twelve month cash flow than 93.86% of its sector Healthcare.
Gilead Sciences Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
HAPP, JNJ, QDEL, CPIX, and ILMN can be thought of as valuation peers to GILD, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
New month... new stock considerations. I can't believe that October is already here... the final quarter of 2020. Seeing how fast time blows by simply reminds me to stay invested no matter how crazy the market seems to be. We have witnessed some pretty harsh declines this year only to...
The Latest: President Donald Trump is being treated with antiviral drug, Gilead's (GILD) remdesivir, at a U.S. military hospital, while campaign manager Bill Stepien and ex-White House adviser Kellyanne Conway have also tested positive.The president is also taking Regeneron's antibody cocktail as reported last night.Senators Thom Tillis from North Carolina and Mike...
The European drugs regulator said on Friday its safety committee was reviewing reports of acute kidney injury in some COVID-19 patients who had been given Gilead Sciences Inc's remdesivir. Kidney injury can be caused by COVID-19 as well as other factors such as diabetes, the EMA said in a statement.
Reports and Data has added a new report titled Global T-Cell Therapy Market to its ever-expanding repository, which aims to offers valuable insights into the T-Cell Therapy industry with regards to the market share, market size, market valuation, and regional